Ichor crowd-funding initiative to receive matching contributions

Syracuse, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today the initiation of its first crowd-funding campaign. The company aims to raise at least $19,500 to study the effects of c60, a potent antioxidant, on human cancer proliferation. Longecity.org and a private donor have pledged two dollars in additional contributions for every dollar raised by the campaign.

Kelsey Moody, CEO at Ichor Therapeutics, said, “We are incredibly grateful to Longecity for their support, and for the opportunity to continue to pursue research on human aging.” He further noted, “C60 is a widely used supplement that may have numerous applications in the treatment of age-related disease. However, its effects on human cancer proliferation are currently unknown, and must be determined.”

This crowd-funding campaign comes just a month after Ichor announced a $383,000 research contract with BioSenex, Ltd. to study the effects of select supplements on aging in mice, including c60. To learn more about the Ichor Therapeutics crowd-funding campaign or to make a tax-deductible donation, please visit this link.

About Ichor Therapeutics, Inc.: Ichor Therapeutics, Inc. (www.ichortherapeutics.com) is a privately held pre-clinical biotechnology company in Syracuse, NY. Founded in 2013 by then SUNY Upstate Medical University student Kelsey Moody, the company has raised over $1 million to support its research programs. Ichor owns and operates the online store WeCellStuff.com.